DK1940447T3 - Behandling af neurodegenrative lidelser - Google Patents
Behandling af neurodegenrative lidelserInfo
- Publication number
- DK1940447T3 DK1940447T3 DK06793581.7T DK06793581T DK1940447T3 DK 1940447 T3 DK1940447 T3 DK 1940447T3 DK 06793581 T DK06793581 T DK 06793581T DK 1940447 T3 DK1940447 T3 DK 1940447T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- neurodegenrative
- disorders
- neurodegenrative disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05108946 | 2005-09-28 | ||
| PCT/EP2006/066438 WO2007039436A1 (en) | 2005-09-28 | 2006-09-18 | Treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1940447T3 true DK1940447T3 (da) | 2014-01-20 |
Family
ID=37622051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06793581.7T DK1940447T3 (da) | 2005-09-28 | 2006-09-18 | Behandling af neurodegenrative lidelser |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20070072795A1 (da) |
| EP (1) | EP1940447B1 (da) |
| JP (1) | JP5096345B2 (da) |
| KR (1) | KR20080038440A (da) |
| CN (1) | CN101277715B (da) |
| AR (1) | AR055654A1 (da) |
| AU (1) | AU2006298826B2 (da) |
| BR (1) | BRPI0616572A2 (da) |
| CA (1) | CA2622609A1 (da) |
| DK (1) | DK1940447T3 (da) |
| ES (1) | ES2445035T3 (da) |
| IL (1) | IL189853A (da) |
| PL (1) | PL1940447T3 (da) |
| RU (1) | RU2467761C2 (da) |
| SI (1) | SI1940447T1 (da) |
| TW (1) | TWI380824B (da) |
| WO (1) | WO2007039436A1 (da) |
| ZA (1) | ZA200802270B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008002054A1 (es) | 2007-07-17 | 2009-05-29 | Hoffmann La Roche | Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico. |
| AR067537A1 (es) | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Purificacion de polipeptidos pegilados |
| RU2515914C1 (ru) * | 2013-02-12 | 2014-05-20 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика" | Гибридный белок на основе рекомбинантного эритропоэтина человека, обладающий пролонгированным действием (варианты), и способ его получения |
| RU2561050C2 (ru) | 2013-08-28 | 2015-08-20 | Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера |
| AR113091A1 (es) * | 2018-09-27 | 2020-01-22 | Univ Nacional Del Litoral | Eritropoyetina humana modificada |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US644077A (en) * | 1898-08-01 | 1900-02-27 | Farbenfabriken Of Elberfeld Company | Acetyl salicylic acid. |
| FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5968502A (en) * | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| TR200103785T2 (tr) * | 1999-04-13 | 2002-06-21 | The Kenneth S. Warren Institute, Inc. | Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi |
| US6225895B1 (en) * | 1999-05-26 | 2001-05-01 | Floyd E. Bigelow, Jr. | Towed vehicle monitor system |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| MEP90708A (hr) * | 2000-05-15 | 2011-12-20 | Nova farmaceutska smješa | |
| WO2002003848A2 (en) * | 2000-07-10 | 2002-01-17 | Naito Albert T | Method for opening the blood-brain barrier |
| DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| EP1345628B1 (en) * | 2000-12-20 | 2011-04-13 | F. Hoffmann-La Roche AG | Conjugates of erythropoietin (epo) with polyethylene glycol (peg) |
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| US7767643B2 (en) * | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| JP2005534650A (ja) * | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
| MXPA05000063A (es) * | 2002-07-01 | 2005-04-08 | Kenneth S Warren Inst Inc | Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores. |
| US7459436B2 (en) * | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US7718363B2 (en) * | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| JP2007505159A (ja) * | 2003-05-19 | 2007-03-08 | ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド | 延長された治療ウインドウを有する、応答性細胞、組織および器官の保護、回復および増強のための組織保護サイトカイン |
| PL1696947T3 (pl) * | 2003-12-19 | 2014-08-29 | Hoffmann La Roche | Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit |
| ATE488519T1 (de) * | 2005-09-28 | 2010-12-15 | Hoffmann La Roche | Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten |
-
2005
- 2005-09-28 US US11/237,505 patent/US20070072795A1/en not_active Abandoned
-
2006
- 2006-09-18 ES ES06793581.7T patent/ES2445035T3/es active Active
- 2006-09-18 SI SI200631739T patent/SI1940447T1/sl unknown
- 2006-09-18 WO PCT/EP2006/066438 patent/WO2007039436A1/en not_active Ceased
- 2006-09-18 CN CN2006800360941A patent/CN101277715B/zh not_active Expired - Fee Related
- 2006-09-18 DK DK06793581.7T patent/DK1940447T3/da active
- 2006-09-18 CA CA002622609A patent/CA2622609A1/en not_active Abandoned
- 2006-09-18 AU AU2006298826A patent/AU2006298826B2/en not_active Ceased
- 2006-09-18 JP JP2008532719A patent/JP5096345B2/ja not_active Expired - Fee Related
- 2006-09-18 PL PL06793581T patent/PL1940447T3/pl unknown
- 2006-09-18 RU RU2008116309/15A patent/RU2467761C2/ru not_active IP Right Cessation
- 2006-09-18 BR BRPI0616572-9A patent/BRPI0616572A2/pt not_active Application Discontinuation
- 2006-09-18 EP EP06793581.7A patent/EP1940447B1/en not_active Not-in-force
- 2006-09-18 KR KR1020087007412A patent/KR20080038440A/ko not_active Ceased
- 2006-09-25 TW TW095135363A patent/TWI380824B/zh not_active IP Right Cessation
- 2006-09-26 AR ARP060104198A patent/AR055654A1/es not_active Application Discontinuation
-
2008
- 2008-02-28 IL IL189853A patent/IL189853A/en not_active IP Right Cessation
- 2008-03-10 ZA ZA200802270A patent/ZA200802270B/xx unknown
- 2008-09-19 US US12/284,277 patent/US20100267632A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL1940447T3 (pl) | 2014-04-30 |
| AU2006298826B2 (en) | 2010-04-01 |
| ES2445035T3 (es) | 2014-02-27 |
| KR20080038440A (ko) | 2008-05-06 |
| RU2467761C2 (ru) | 2012-11-27 |
| EP1940447B1 (en) | 2013-11-27 |
| US20100267632A1 (en) | 2010-10-21 |
| JP2009510008A (ja) | 2009-03-12 |
| CA2622609A1 (en) | 2007-04-12 |
| AU2006298826A1 (en) | 2007-04-12 |
| AR055654A1 (es) | 2007-08-29 |
| RU2008116309A (ru) | 2009-11-10 |
| SI1940447T1 (sl) | 2014-03-31 |
| IL189853A (en) | 2012-06-28 |
| WO2007039436A1 (en) | 2007-04-12 |
| TWI380824B (zh) | 2013-01-01 |
| EP1940447A1 (en) | 2008-07-09 |
| ZA200802270B (en) | 2009-02-25 |
| US20070072795A1 (en) | 2007-03-29 |
| CN101277715B (zh) | 2013-03-27 |
| JP5096345B2 (ja) | 2012-12-12 |
| IL189853A0 (en) | 2008-11-03 |
| BRPI0616572A2 (pt) | 2009-11-24 |
| CN101277715A (zh) | 2008-10-01 |
| TW200727911A (en) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1720866T3 (da) | Fremgangsmåde | |
| EP1845849A4 (en) | EXISCELET FOR THE LEGS | |
| EP1874239A4 (en) | HALF-POWERED EXOSCELETT OF LOWER EXTREMITY | |
| DK1874781T3 (da) | Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme | |
| DK1890684T3 (da) | Behandling af søvn/vågenhedsforstyrrelser | |
| DK1986633T3 (da) | Behandling af duchennes muskeldystrofi | |
| DK2056807T3 (da) | Behandling af inflammatoriske sygdomme | |
| DK1869025T3 (da) | Piperazin-substituerede benzothiophener til behandling af mentale lidelser | |
| DK2084151T3 (da) | Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme | |
| NO20070251A (no) | Brønnbehandling | |
| NO20070297A (no) | Brønnbehandling | |
| FI20060708L (fi) | Hierontalaite | |
| DK1938528T3 (da) | Provision af qos-behandling baseret på flere anmodninger | |
| CY2200156T2 (el) | Επεξεργασια λυματων | |
| DK1708992T3 (da) | Sulfonamidderivater til behandling af sygdomme | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK1685834T3 (da) | Anvendelse af pinolensyre til behandling af obesitet | |
| BRPI0715728A8 (pt) | tratamento de distúrbios cartilaginosos | |
| DK2056858T3 (da) | Behandling af lungesygdomstilstande | |
| DK1948176T3 (da) | Diarylurinstoffer til behandling af pulmonær hypertension | |
| DK2117565T3 (da) | Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme | |
| DK2175849T3 (da) | Behandling af melanomer | |
| DK1982178T3 (da) | Fremgangsmåder til behandling af affektbetonede lidelser | |
| DK1962869T3 (da) | Behandling af luftvejssygdomme | |
| NO20055643D0 (no) | Preparation of lodixanol |